Before starting any GLP-1 compoundwhether semaglutide, tirzepatide, or a dual formulationunderstanding your baseline triglyceride level, lipid panel, and metabolic predispositions can help your provider determine whether triglyceride improvement is a realistic goal and what timeline to expect
Other agents in development include mazdutide , cagrilintide , survodutide, and orforglipron (an oral small-molecule GLP-1 agonist)
Both forms contain the same active ingredient, semaglutide, and work similarly to help control appetite and promote weight loss
When switching, always initiate at the lowest dose unless instructed otherwise by your healthcare provider
Compounded GLP-1 medications operate under FDA section 503A oversight and state pharmacy regulation